# US 2021/0261647 A1 · Lamp constructs comprising allergens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261647 A1
- Document ID: US20210261647A1
- Status: Published application
- Kind: A1
- Application number: 17/053,784
- Filed: 2019-05-14
- Published: 2021-08-26
- Earliest claimed: 2018-05-15
- Assignees: Immunomic Therapeutics, Inc.
- Applicants: Immunomic Therapeutics, Inc
- Inventors: Teri HEILAND
- Web page: https://patentgrep.com/patent/US20210261647A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61K 39/35: Allergens
- A61K 39/36: from pollen
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/415: from plants
- C07K 14/43509: {from crustaceans}
- C07K 14/43531: {from mites}
- C07K 14/43568: {from wasps}
- C07K 14/43572: {from bees}
- C07K 14/4359: {from fleas}
- C07K 14/47: from mammals
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver allergens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular allergic reactions and/or allergies. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs.

## Claims

### Claim 1

An improved LAMP Construct comprising:
a. a Cysteine Conserved Fragment of a LAMP Protein; and
b. at least one Allergen X (SEQ ID NO:Y) as described in Table 1/FIG. 14.

### Claim 2 (depends on 1)

The improved LAMP Construct of claim 1, wherein:
a. Allergen X (SEQ ID NO:Y) is placed at the N-terminus of the Cysteine Conserved Fragment;
b. Allergen X (SEQ ID NO:Y) is place at the C-terminus of a single Cysteine Conserved Fragment; or
c. Allergen X (SEQ ID NO:Y) is placed in between two Cysteine Conserved Fragments.

### Claim 3 (depends on 1)

The improved LAMP Construct of claim 1, wherein the improved LAMP Construct comprises at least one of Allergen X (SEQ ID NO:Y) of Table 1/FIG. 14, and preferably is constructed as depicted in ILC-1, ILC-2, ILC-3, ILC-4, ILC-5 or ILC-6.

### Claim 4 (depends on 3)

The improved LAMP Construct of claim 3, wherein each Allergen X (SEQ ID NO:Y) is separated by a linker.

### Claim 5 (depends on 4)

The improved LAMP Construct of claim 4, wherein the linker is selected from the amino acid sequence GPGPG or PMGLP.

### Claim 6 (depends on 1)

The improved LAMP Construct of claim 1, wherein the improved LAMP Construct comprises more than one Cysteine Conserved Fragment.

### Claim 7 (depends on 1)

The improved LAMP Construct of claim 1, wherein the Cysteine Conserved Fragment comprises a Homology Domain of a LAMP Protein.

### Claim 8 (depends on 1)

The improved LAMP Construct of claim 1, wherein the improved LAMP Construct further comprises a Transmembrane Domain of a LAMP Protein.

### Claim 9 (depends on 1)

The improved LAMP Construct of claim 1, wherein the improved LAMP Construct further comprises a signal sequence.

### Claim 10 (depends on 9)

The improved LAMP Construct of claim 9, wherein the signal sequence is derived from a LAMP Protein.

### Claim 11 (depends on 1)

The improved LAMP Construct of claim 1, wherein the LAMP protein is selected from LAMP-1, LAMP2, LAMP-3, LIMP 2, Macrosailin, Endolyn, LAMP5 or LIMBIC.

### Claim 12 (depends on 11)

The improved LAMP Construct of claim 11, wherein the LAMP Protein is selected from any one of SEQ ID NO:1-250 and/or the Allergen X is selected from any one of SEQ ID NO:Y.

### Claim 13 (depends on 12)

The improved LAMP Construct of claim 12, wherein the LAMP Protein is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:1-113 and/or the Allergen X is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:Y.

### Claim 14 (depends on 1)

A polynucleotide encoding the improved LAMP Construct of claim 1.

### Claim 15 (depends on 14)

A host cell comprising the polynucleotide of claim 14.

### Claim 16 (depends on 1)

A composition comprising the improved LAMP Construct of claim 1.

### Claim 17 (depends on 1)

A method of treating an allergic response in a subject in need thereof, wherein the method comprises administering to a subject the improved LAMP Construct of claim 1 in an amount sufficient to reduce or treat the disease or disorder.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method comprises a priming step and at least one boosting step.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18)

The method of claim 18, wherein the improved LAMP Construct of any one of claims 1-13, the polynucleotide of claim 14, the host cell of claim 15, or the composition of claim 16 is used in the priming step.

### Claim 20 (depends on 18)

The method of claim 18, wherein the boosting step comprises administration of Allergen X, an improved LAMP Construct, a polypeptide encoded by an improved LAMP Construct, or a cell comprising the improved LAMP Construct.

### Claim 21 (depends on 17)

The method of claim 17, wherein Allergen X used to prime is the same that is used to boost.

### Claim 22 (depends on 17)

The method of claim 17, wherein Allergen X used to prime is derived from the same protein as a second Allergen X used to boost.

### Claim 23 (depends on 17)

The method of claim 17, wherein more than one Allergen X is used to prime and/or boost.
